The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity

Huynh, Mai Anh; Crane, Meredith J.; Jamieson, Amanda M.

doi:10.3389/fimmu.2022.1094110

Cited by 8 publications

(5 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While these avenues are promising, it is essential to note that the development of metal-based drugs as therapies for microbiome modulation is in its nascent stages. Moreover, the link between microbiome modulation and cancer prevention remains a complex issue that requires more research [118,120,329,330]. While it is known that chronic inflammation can contribute to cancer development and that bacterial imbalances in the lungs can drive this inflammation, it is not yet entirely clear how effectively and consistently altering the microbiome can reduce cancer risk.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs

O’Shaughnessy,

Sheils,

Baird

2023

IJMS

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most prevalent and debilitating respiratory diseases worldwide, both associated with high morbidity and mortality rates. As major global health concerns, they impose a substantial burden on patients, healthcare systems, and society at large. Despite their distinct aetiologies, lung cancer and COPD share common risk factors, clinical features, and pathological pathways, which have spurred increasing research interest in their co-occurrence. One area of particular interest is the role of the lung microbiome in the development and progression of these diseases, including the transition from COPD to lung cancer. Exploring novel therapeutic strategies, such as metal-based drugs, offers a potential avenue for targeting the microbiome in these diseases to improve patient outcomes. This review aims to provide an overview of the current understanding of the lung microbiome, with a particular emphasis on COPD and lung cancer, and to discuss the potential of metal-based drugs as a therapeutic strategy for these conditions, specifically concerning targeting the microbiome.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs

O’Shaughnessy,

Sheils,

Baird

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…is a Gram-negative bacterium that has been previously associated with nosocomial infections, and some studies have suggested a potential link between pathogenic bacteria such as Acinetobacter spp. and lung cancer development or progression [27,28]. Further studies are needed to explore the potential role of Acinetobacter spp.…”

Section: Important Findingsmentioning

confidence: 99%

Bronchial Microbiota and the Stress Associated with Invasive Diagnostic Tests in Lung Cancer vs. Benign Pulmonary Diseases: A Cross-Sectional Study

Hogea,

Tudorache,

Fira-Mladinescu

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide. This study aimed to compare the bronchial microbiota of patients with lung cancer and patients with benign pulmonary diseases undergoing bronchoscopy, and to assess the stress levels associated with invasive diagnostic lung tests. A cross-sectional study was conducted at the “Victor Babes” Hospital for Infectious Diseases and Pulmonology in Timisoara, Romania. A total of 33 patients with histologically diagnosed bronchopulmonary cancer and 33 control patients with benign lung pathologies underwent bronchoscopy. Bronchial microbiota was analyzed by multiplex PCR, culture media, and cytology. Anxiety and depression levels were assessed using the ECOG performance status scale, Karnofsky scale, GAD-7, PHQ-9, and HADS questionnaires. There were no significant differences in the presence of common microbial species between the two groups, except for Acinetobacter spp. Which was identified in 15.2% of patients with lung cancer and 0.0% in the control group, Candida spp. Was more prevalent in the benign group (24.2% vs. 6.1%), and the Parainfluenza virus was detected only in the malignant group (21.1% vs. 0.0%). Cytology results showed a higher prevalence of atypical and tumoral cells in the malignant group (39.4% and 30.0%, respectively), as well as higher lymphocyte levels in the benign group (69.7% vs. 24.2%). Patients with lung cancer had significantly lower performance status on the ECOG scale (2.34 vs. 1.92), lower Karnofsky scores (71.36 vs. 79.43), and higher GAD-7 and PHQ-9 scores at the initial evaluation compared to the benign group. At the 90-day follow-up, ECOG and Karnofsky scores remained significantly different from the initial evaluation, but only GAD-7 scores showed a significant difference between the two groups. There were differences in the bronchial microbiota between patients with lung cancer and benign pulmonary diseases, with a higher prevalence of Candida spp. in the benign group and exclusive detection of Acinetobacter spp. and Parainfluenza virus in the malignant group. Patients with lung cancer exhibited higher stress levels, more severe anxiety, and depression symptoms, which persisted during follow-up. Further research is needed to understand the role of bronchial microbiota in lung cancer and the impact of stress on patient outcomes.

show abstract

“…Although the emergence of immunotherapy has provided a chance of survival for patients with advanced disease, 60% of patients do not have immunotherapy driver genes, and even the immune response rate of patients with NSCLC is only 15-25% ( 2 ).In addition, some patients undergo immunotherapy for a certain period and develop immune escape, while others discontinue treatment due to severe immune-related adverse effects ( 3 ). If the disease is diagnosed early, the five-year survival rate of lung cancer patients can be increased to 59% ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…The microbiota is a community of all microbial species, including bacteria, fungi, viruses, archaea, and protozoa. Depending on their preferences for nourishment and oxygen, different microbes are often found on human body surfaces that come into touch with the external environment, including the skin, mouth, respiratory system, gastrointestinal tract, and urine tract ( 4 ). The human microbiota begins to colonize at birth.…”

Section: Introductionmentioning

confidence: 99%

Microbes for lung cancer detection: feasibility and limitations

Zhou,

Zhu,

Guo

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

As the second most common cancer in the world, the development of lung cancer is closely related to factors such as heredity, environmental exposure, and lung microenvironment, etc. Early screening and diagnosis of lung cancer can be helpful for the treatment of patients. Currently, CT screening and histopathologic biopsy are widely used in the clinical detection of lung cancer, but they have many disadvantages such as false positives and invasive operations. Microbes are another genome of the human body, which has recently been shown to be closely related to chronic inflammatory, metabolic processes in the host. At the same time, they are important players in cancer development, progression, treatment, and prognosis. The use of microbes for cancer therapy has been extensively studied, however, the diagnostic role of microbes is still unclear. This review aims to summarize recent research on using microbes for lung cancer detection and present the current shortcomings of microbes in collection and detection. Finally, it also looks ahead to the clinical benefits that may accrue to patients in the future about screening and early detection.

show abstract

The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity

Cited by 8 publications

References 133 publications

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs

Bronchial Microbiota and the Stress Associated with Invasive Diagnostic Tests in Lung Cancer vs. Benign Pulmonary Diseases: A Cross-Sectional Study

Microbes for lung cancer detection: feasibility and limitations

Contact Info

Product

Resources

About